Filana Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Filana Therapeutics, Inc. (FLNA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $15.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-12
- Filana Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $15.10M, a 22.16% decline from fiscal 2024.
- Filana Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $19.40M, a 16.74% decline from fiscal 2023.
- Filana Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $23.30M, a 130798.88% increase from fiscal 2022.
- Filana Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $17.80K, a 99.77% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $15.10M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $19.40M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $23.30M 10-K · filed 2025-03-03 | $23.30K 10-K · filed 2024-02-28 |
| 2022-12-31 | $17.80K 10-K · filed 2024-02-28 | $17.80M 10-K · filed 2023-02-28 |
| 2021-12-31 | $7.70M 10-K · filed 2023-02-28 | |
| 2020-12-31 | -$1.30M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $900.00K 10-K · filed 2020-03-26 | |
| 2018-12-31 | $1.30M 10-K · filed 2020-03-26 | |
| 2017-12-31 | $10.30M 10-K · filed 2019-03-29 | |
| 2016-12-31 | $3.60M 10-K · filed 2018-02-06 | |
| 2015-12-31 | $3.40M 10-K · filed 2017-03-07 | |
| 2014-12-31 | $3.20M 10-K · filed 2016-03-03 | |
| 2013-12-31 | -$14.60M 10-K · filed 2015-02-18 | $15.00M 10-K · filed 2014-02-05 |
| 2012-12-31 | $3.10M 10-K · filed 2014-02-05 | |
| 2011-12-31 | $800.00K 10-K · filed 2014-02-05 | |
| 2010-12-31 | $4.50M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |